Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | No. 4 The Forum, Grenville Street SAINT HELIER JE2 4UF |
Tel: | N/A |
Website: | https://www.novocure.com |
IR: | See website |
Key People | ||
William F. Doyle Executive Chairman of the Board | Asaf Danziger President, Chief Executive Officer, Director | Ashley Cordova Chief Financial Officer |
Wilhelmus C. M. Groenhuysen Chief Operating Officer | William Burke Chief Human Resource Officer | Frank X. Leonard Executive Vice President and President - Novocure Oncology |
Barak Ben-Arye General Counsel | Nicholas Leupin Chief Medical Officer | Uri Weinberg Chief Innovation Officer |
Business Overview |
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. |
Financial Overview |
For the three months ended 31 March 2024, Novocure Ltd revenues increased 13% to $138.5M. Net loss decreased 27% to $38.8M. Revenues reflect Other EMEA countries segment increase from $7.9M to $19.5M, United States segment increase of 6% to $90.5M. Lower net loss reflects Research, development and clinical decrease of 10% to $43M (expense), Stock-based Compensation in R&D decrease of 27% to $8.6M (expense). |